Rocket Pharmaceuticals (RCKT) Reports Preliminary Data from Phase 1/2 Trial of RP-L201 for Leukocyte Adhesion Deficiency-I

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. SPCX
3. MU
4. SPY
5. ACN
6. IBM
7. PRIM
8. PFE
9. TSLA
10. DPZ

Go back to Rocket Pharmaceuticals (RCKT) Reports Preliminary Data from Phase 1/2 Trial of RP-L201 for Leukocyte Adhesion Deficiency-I

Rocket Pharmaceuticals Announces Preliminary Data from Phase 1/2 Trial of RP-L201 for Leukocyte Adhesion Deficiency-I

December 9, 2019 7:00 AM EST

- Initial Data Demonstrated Robust CD18 Expression and Resolution of Disease-Mediated Lesions in Months After Gene Therapy Treatment -

NEW YORK--(BUSINESS WIRE)-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (Rocket), a... More